💊 Orforglipron: A new era in obesity treatment?

In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️

🔥 Nearly 1 in 5 patients lost ≥20% body weight

💡 A promising alternative to injectable therapies

Accessible. Effective. Oral.

👉 A game-changer for global obesity care?

#Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM #Innovation #ClinicalTrials #Endocrinology #PublicHealth #Pharmacotherapy

🚨 New Podcast Drop! 🎙️

"Myosin, Metrics & Momentum 🧬📈🫀" dives into 3 landmark NEJM articles on Aficamten vs Mavacamten in hypertrophic cardiomyopathy.

We decode:

🔹 MAPLE-HCM (obstructive HCM)

🔹 ODYSSEY-HCM (nonobstructive HCM)

🔹 Expert editorial insights on PROs, EF, & trial design

🎯 Learn what matters: peak VO₂ vs PROs, safety signals, and the road ahead in precision cardiomyopathy care.

🎧 Tune in and share! #HCM #CardioTwitter #NEJM #HeartFailure #MyosinInhibitors #Podcast

💊 New Hope in a Pill for Obesity?

The 71-week OASIS 4 trial shows that oral semaglutide 25 mg led to a 13.6% weight loss, improved physical function, and reversed prediabetes in 71% of cases—all without injections.

📉 Effective. 🧬 Metabolically beneficial. 📦 Orally delivered.

#ObesityCare #GLP1 #Semaglutide #NEJM #DigitalHealth #Cardiometabolic

☀️ Walking on Sunshine? Rethinking Our Relationship with the Sun! 🧴🧬

New research—spotlighted in The Economist (Sep 20, 2025)—challenges old assumptions: Could moderate sun exposure reduce cardiovascular mortality? ❤️📉

From nitric oxide to vitamin D, this FAQ explores the science, nuance, and shifting global guidelines.

Let's talk melanin, mortality, and medicine! 🌍💡

#Sunlight #CardiovascularHealth #TheEconomist #PublicHealth #MedicalEducation

🚨 Cardiogenic Shock—A Decade Later

The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone.

📉 Mortality: 52.5% vs 68.8% (HR 0.70)

🛠️ Despite higher adverse events, the survival benefit endured a full decade.

📊 This changes how we think about long-term outcomes in mechanical support.

🔗 Time to revisit your shock protocols?

#DanGerShock #Impella #CardiogenicShock #STEMI #LongTermOutcomes #NEJM #MCS #Cardiology #SurvivalBenefit #ImpellaCP

🧠 Hypertrophic Cardiomyopathy — A Masterclass from Eugene Braunwald 🧬

📌 Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM — from Teare's first autopsy to myosin inhibitors, AI diagnostics, and gene therapy.

💥 Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advances—all distilled into one must-read.

📉 SCD prevention, 🫀 LVOT obstruction, 🧪 MYBPC3/MYH7 mutations, 🧬 proteomics, and more.

🔗 Essential reading for cardiologists, geneticists, and translational scientists.

#HCM #Braunwald #NEJM #Cardiology #PrecisionMedicine #Mavacamten #Aficamten #GeneTherapy #MedicalEducation #SCDprevention

🚨 New NEJM Study on Olezarsen 🚨

In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥

✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol

✅ No rise in LDL-C

✅ Well-tolerated with mild injection-site reactions

🔬 APOC3 inhibition emerges as a game-changer in lipidology.

📖 ESSENCE–TIMI 73b Trial | Funded by Ionis Pharmaceuticals

#Cardiology #LipidLowering #PrecisionMedicine #NEJM #Olezarsen #TGlowering #CVRisk #TIMI #Atherosclerosis #GenomicTherapy 🧬💊🫀

🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—"just sitting" 🧘‍♂️—where enlightenment and practice are inseparable.

His Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨

#Zen #Mindfulness

🚨 New Evidence in NSTEMI Care! 🫀

The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI.

🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again.

📚 Published in JAMA, presented at #ESC2025

🔗 Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189

#Cardiology #NSTEMI #FFR #InterventionalCardiology #EvidenceBasedMedicine #SLIMTrial

💥 Practice-Changing Evidence in HFpEF! 💥

In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉

⚖️ No meaningful difference between the two agents.

🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies' expanding role in cardiometabolic HFpEF 🫀

#Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure